Rhabdomyolysis …

Neuromuscular Disorders

Updated 10.10.2023
Released 09.06.1993
Expires For CME 10.10.2026

Rhabdomyolysis (myoglobinuria)

Authors: Mohamed Kazamel MD, Carmela San Luis MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Rhabdomyolysis (myoglobinuria)

In This Article

Quick Link

Introduction

Overview

Rhabdomyolysis refers to the breakdown of striated muscle that is followed by leakage of the muscle protein myoglobin into the blood, leading to its excretion in the urine. This phenomenon is called myoglobinuria. The etiology of rhabdomyolysis is diverse and includes hereditary (metabolic diseases, dystrophinopathies, channelopathies) and acquired disorders (excessive muscular stress, ischemia, toxic damage, infections). Epidemiologic studies have shown that the etiology of a significant percentage of patients with recurrent rhabdomyolysis remains unknown. It is thought that these patients may have undiscovered muscle metabolism disorders. In this article, the authors review the epidemiology of rhabdomyolysis in the adult and pediatric populations, the metabolic causes leading to recurrent rhabdomyolysis, and some preventive and treatment strategies employed for this condition.

Key points

	• Extensive work-up for rhabdomyolysis is indicated for recurrent or family history of rhabdomyolysis and myalgia or muscle cramps, especially at rest.
	• The most common cause of the first episode of rhabdomyolysis in an adult who does not report a history of earlier significant exertion is drugs.
	• The most common etiologies of rhabdomyolysis in the pediatric population are trauma and viral myositis.
	• It is always recommended to wait 4 to 6 weeks after an episode of rhabdomyolysis is resolved to obtain a muscle biopsy.
	• Knowing the baseline creatinine kinase (CK) in a patient who has known chronic muscle disease with recurrent rhabdomyolysis is important.

Historical note and terminology

Muscle tissues contain the oxygen-binding protein myoglobin. When striated muscles break down or rhabdomyolysis occurs, muscle cell content leaks into the blood, including myoglobin, leading to the excess amount excreted into the urine. This phenomenon is called myoglobinuria (18). The clinical presentation is variable. The classical features are myalgia, weakness, pigmenturia, or dark tea-colored urine. However, this triad is seen in only 10% to 18% of patients (51). The urine becomes pigmented with a brownish color when myoglobin concentration is over 100 µg/mL (09).

The term rhabdomyolysis has been employed increasingly since the 1960s to denote the abrupt muscle injury that causes myoglobinuria. Thus, myoglobinuria and rhabdomyolysis are used interchangeably because myoglobinuria would not occur without rhabdomyolysis (18; 55). In a systematic review by Chavez and colleagues, there was heterogeneity in the diagnostic criteria of rhabdomyolysis (16). However, most studies defined rhabdomyolysis as an elevation of serum creatine kinase (CK) level of at least five times the upper limit of normal (greater than 1000 U/L) followed by its decrease to (near) normal values. Some use a CK level greater than 10 times the upper limit of normal to guide the need for hospitalization (55). However, as CK level may be affected by other factors, there should be caution in diagnosing acute rhabdomyolysis in patients with cardiac diseases, chronic kidney disease, stroke or status epilepticus, and chronic neuromuscular disease (84). Having a baseline CK in these settings would be of high value.

Pigmenturia, in association with symptoms of muscle injury, was recognized in the German literature in the late 19th century as a disorder that affected horses and humans (32). Over the first half of the 20th century, biochemical studies led to the identification and characterization of the muscle heme protein, myoglobin and elucidation of its role in transporting oxygen from hemoglobin to mitochondria (40). Parallel clinical observations established more firmly the link between muscle injury and the urinary excretion of myoglobin and began to outline the epidemiology of this syndrome. Of special note are the studies of Bywaters, which identified rhabdomyolysis as a complication of muscle crush injuries sustained in the Battle of Britain in World War II; he described acute renal failure as a rhabdomyolysis complication and performed seminal experimental studies implicating myoglobin (rather than other constituents of injured muscle) in the pathogenesis of renal injury (12).

Clinical manifestations

Presentation and course

Muscle symptoms. The acute skeletal muscle injury that produces rhabdomyolysis typically causes myalgia and muscle swelling, the latter attributable to a shift of extracellular fluid into necrotic muscle. The severity of these symptoms is conditioned by the extent and location of muscle injury. With severe generalized muscle injury, the patient is prostrate, is unable to move because of widespread muscle pain and weakness, and has tight, swollen muscles causing stiffness and exquisite pain to muscle palpation or attempted movement (48). Compared to common muscle soreness, the weakness and stiffness seem more acute and sustained in rhabdomyolysis. Also, pain tends to be present even at rest in rhabdomyolysis and abates with rest in muscle soreness (69). In other circumstances, muscle injury and symptoms may be focal. Muscle swelling in a restricted anatomic region may lead to a compartment syndrome in which the swelling blocks muscle blood flow, leading to a “second wave” of ischemic muscle necrosis and further swelling that ultimately leads to neural and vascular injury (48). Organ failure can occur, depending on the extent and severity of muscle damage, and is the cause of death in about 8% of cases (11). At the other extreme, muscle symptoms may be relatively minor or overshadowed by complications of rhabdomyolysis or by symptoms of the acute event or illness that triggered muscle injury (26).

Renal manifestations. The most important complication is acute kidney injury or acute renal failure, occurring in 13% to 50% due to renal vasoconstriction, intraluminal cast formation, and direct myoglobin toxicity (94; 72). Pigmenturia typically occurs in close temporal relation to the acute muscle injury or when circulation is restored to necrotic muscle and is attributable to the release of myoglobin into the bloodstream with rapid clearance by the kidney. Oliguria may herald the onset of acute renal failure. The likelihood of renal failure is greatly increased by the presence of hypotension, decreased renal perfusion, dehydration, acidosis, or nephrotoxic drugs (18). Increased serum levels of myoglobin greater than 15,000 micrograms/L were also found to correlate significantly with developing acute kidney injury in both adult and pediatric groups (75; 72; 51).

Other symptoms and complications. With catastrophic rhabdomyolysis, hypotension or shock may occur because of large fluid shifts (third spacing). In these instances, the common finding of acute hypoalbuminemia probably indicates an associated endothelial injury. Cardiac arrhythmia may occur because of hyperkalemia due to potassium release from necrotic muscle and renal compromise. Aside from hyperkalemia, other electrolyte abnormalities can also be observed: hypocalcemia, hypercalcemia, hyponatremia, hyperphosphatemia, and metabolic acidosis (72). Disseminated intravascular coagulation, possibly attributable to thromboplastin release from injured muscle, could complicate severe rhabdomyolysis, and hemorrhagic complications may also result. Acute respiratory distress syndrome attributable to the involvement of muscles of respiration or to pulmonary capillary hyperpermeability has been described. Ischemic or infarcted bowel has also been reported.

Skin changes of ischemic tissue injury, such as discoloration or blisters, may also be seen but are present in less than 10% of patients (33).

Laboratory findings. The major laboratory features of myoglobinuria are pigmenturia and elevation of cytoplasmic enzymes liberated from injured muscle. The myoglobin level in urine is a function of the mass of injured muscle and the rate of urine flow. Visible discoloration of the urine is apparent with myoglobin concentrations of 100 µg/mL; levels above 1 µg/mL are detectable by peroxidase-sensitive chromogens such as orthotolidine. This qualitative measurement utilizes urine dipstick testing for blood on an ultrafiltrated or precipitated urine sample. This extra step removes hemoglobin and assumes a positive result is due to myoglobin. However, due to false positive and negative results, utilization of this has declined (82). False negatives may occur with high specific gravity, ascorbic acid, or high nitrite concentration (28). Radioimmune assay quantitatively detects myoglobin to about 5 ng/mL. Normal serum levels are 30 to 80 micrograms/L, whereas urine levels are 3 to 20 micrograms/L. Myoglobinuria is diagnosed when urine concentrations exceed 20 micrograms/L (18; 72). A study by Schifman and Luevano found that reflex testing of urinalysis with a negative or trace hemoglobin count averted over-testing using quantitative methods (82).

The rhabdomyolysis period is generally brief (hours). Creatine kinase levels tend to peak 24 to 72 hours after the acute injury (84), usually reaching levels of 10s to 100s of thousand international units (IU) per liter. CK levels then decline by about 50% approximately every 48 hours. Serum aldolase, transaminases, and lactate dehydrogenase are correspondingly elevated. Additional laboratory abnormalities may include hyperkalemia, particularly in the setting of renal failure; hyperphosphatemia; hypocalcemia related to the deposition of calcium salts in injured muscle; and hyperuricemia. Myoglobinuric renal failure characteristically produces a disproportionately elevated creatinine relative to blood urea nitrogen. Hemoconcentration accompanies fluid shifts into injured muscle.

Although the pathologic processes responsible for rhabdomyolysis are diverse, the histologic features often are similar. Typically, a population of muscle fibers shows evidence of injury and are all at a similar stage of necrosis or regeneration depending on the timing of the biopsy, consistent with injury affecting a susceptible population of muscle fibers within a limited time frame. A biopsy temporally remote from the episode of rhabdomyolysis (4 to 6 weeks later) commonly reveals virtually normal muscle morphology, reflecting the remarkable regenerative capacity of skeletal muscle. It may also reveal the underlying cause (metabolic, mitochondrial myopathy, etc.)

Prognosis and complications

Massive muscle injury triggered by severe exertion or myotoxins may result in multiple organ failure and death. However, rhabdomyolysis generally has a good prognosis if renal failure is avoided or aggressively treated. Muscle has a remarkable capacity to regenerate, and most patients recover muscle function fully. Even patients who have had multiple episodes of rhabdomyolysis may have no lasting skeletal muscle effects. However, muscle weakness and focal loss of muscle mass, possibly attributable to recurrent muscle injury, could occur late in life in muscle phosphorylase deficiency and muscle phosphofructokinase deficiency.

Clinical vignette

After an hour of unaccustomed weightlifting to “get in shape,” a 28-year-old white male experienced pain affecting muscles of the upper arms, chest, and back. Urine was noted to be Coca-Cola colored on voiding an hour later. Twelve hours later, the patient's arms were swollen, and it hurt to move them. He felt generally unwell and nauseated and was treated symptomatically for possible flu. The following day on presentation to an emergency room, creatine kinase was 100,000 IU, and serum creatinine and blood urea nitrogen were elevated. The patient underwent hemodialysis for acute renal failure. The admitting physician obtained a history of virtually lifelong exercise intolerance. An ischemic forearm test showed no lactate increase, and a subsequent muscle biopsy revealed absent muscle phosphorylase reactivity (McArdle disease). Genetic testing showed compound heterozygous missense and nonsense mutations (p.R50X) in the PYGM gene.

Biological basis

Etiology and pathogenesis

The number of hereditary and acquired disease processes that may produce rhabdomyolysis, including drugs, toxins, and underlying metabolic errors, is continually expanding (Tables 1 and 2). Correspondingly, rhabdomyolysis has gone from a medical oddity to a commonly recognized event.

The main hereditary disorders predisposing to recurrent episodes of rhabdomyolysis include inborn errors of muscle metabolism affecting carbohydrate or lipid metabolism. These disorders may present with exercise intolerance, cramps, or rhabdomyolysis. In muscle glycogenolytic or glycolytic defects, rhabdomyolysis is typically triggered by brief intense exercise. The responsible metabolic defects are deficiency of phosphorylase (McArdle), phosphofructokinase (Tarui), phosphoglycerate mutase, phosphoglycerate kinase (21), lactate dehydrogenase, phosphorylase b kinase (22), and phosphoglucomutase (63).

The major lipid disorder causing recurrent rhabdomyolysis is carnitine palmitoyltransferase II deficiency (22). Prolonged and submaximal exercise, particularly when associated with fasting, is most often implicated; intercurrent infection may also trigger muscle injury in this disorder. Approximately two thirds of patients with fatty acid oxidation defects suffer from episodic myalgias, elevated creatine kinase, and myoglobinuria (78). Fatty acid oxidation defects disrupting the oxidation of long-chain fatty acids are more often associated with recurrent rhabdomyolysis, whereas enzyme deficiencies disrupting the oxidation of short- and medium-chain fatty acids result in rhabdomyolysis on rare occasions (90; 76; 42; 78) (Table 1).

A disorder involving lipid homeostasis has been described. It involves a muscle-specific phosphatidic acid phosphatase, which is a key enzyme in triglyceride and membrane phospholipid biosynthesis. Patients present in early childhood with recurrent episodes of rhabdomyolysis precipitated by febrile illness.

Mutations in the LPIN1 gene encoding for this enzyme have been detected in these patients (100). It was postulated that secondary accumulation of lysophospholipids during stress periods results in acute rhabdomyolysis.

Respiratory chain and other mitochondrial disorders are increasingly recognized as causes of exercise intolerance with or without rhabdomyolysis. Such conditions include cytochrome c and b oxidase deficiencies, complex I deficiency, complex III deficiency, and primary coenzyme Q10 deficiency (21; 63). Mutations in mtDNA, including multiple deletions or point mutations in tRNA genes, have also been associated with recurrent rhabdomyolysis (88; 53; 23). A deficiency of the lipoamide dehydrogenase enzyme was characterized by recurrent attacks of vomiting, abdominal pain, and encephalopathy accompanied by elevated liver transaminases, prolonged prothrombin time, and occasionally associated with lactic and ketoacidemia or with rhabdomyolysis (83).The E3 subunit of the pyruvate dehydrogenase complex, dihydrolipoamide dehydrogenase/dihydrolipoyl dehydrogenase (DLD)/lipoamide dehydrogenase (LAD), is a mitochondrial matrix enzyme and a part of the branched-chain ketoacid dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. DLD deficiency is relatively frequent in the Ashkenazi Jewish population but occurs in other populations as well. Data was gathered from the files of 17 pediatric patients with DLD deficiency, confirmed by enzymatic and genetic analysis in an Israeli study in 2013 (31).

A previously described disorder in patients from Northern Sweden had been characterized by exercise intolerance and rhabdomyolysis and associated with succinate dehydrogenase and aconitase deficiency (52; 29) and was later elucidated as a defect in the iron-sulfur cluster scaffold protein (ISCU) (60). These patients present depletion of mitochondrial ISCU in muscle that leads to a deficiency in mitochondrial iron-sulfur proteins and impaired muscle oxidative metabolism.

Other biochemical defects associated with rhabdomyolysis include glucose 6-phosphate dehydrogenase deficiency (pentose pathway) and, rarely, myoadenylate deaminase deficiency (purine nucleotide cycle) (95).

Other causes of hereditary rhabdomyolysis include some skeletal muscle channelopathies, causing hyperexcitability and resulting in susceptibility to malignant hyperthermia (39). Malignant hyperthermia is a genetic predisposition to develop muscle rigidity, hypermetabolism, fever, and rhabdomyolysis triggered by volatile anesthetics or depolarizing muscle relaxants. In most families with this condition, there is linkage to the gene encoding for the skeletal muscle ryanodine receptor (RYR1). RYR1 is a calcium channel mediating calcium release from the sarcoplasmic reticulum during excitation-contraction coupling. To date, more than 45 pathogenic point mutations in RYR1 have been identified (OMIM *180901). Additional chromosomal loci mapped in malignant hyperthermia include the region of a dihydropyridine receptor subunit gene (CACNA1S) (39) and the voltage-gated skeletal muscle sodium channel gene SCN4A (62). Central core disease is often associated with malignant hyperthermia susceptibility and is allelic to malignant hyperthermia due to mutations in the RYR1 gene (39).

Further causes of hereditary rhabdomyolysis include muscular dystrophies. Exercise-induced rhabdomyolysis has been reported in a few cases with dystrophinopathies, including Becker muscular dystrophy, as well as in limb-girdle muscle dystrophies 2C, 2D, and 2E, and sarcoglycanopathies (13). A high incidence of rhabdomyolysis and muscle pain has been reported in limb-girdle muscular dystrophy 2I due to FKRP gene mutations (56). There have also been a few case reports of bisphosphonate-induced rhabdomyolysis in Duchenne muscular dystrophy (34). Dysferlinopathy, ano-5 myopathy, and FSHD also had few reports of recurrent rhabdomyolysis (63). Myotonic dystrophy has been reported in cases of ritodrine-induced rhabdomyolysis (77; 64; 61; 65).

Recurrent rhabdomyolysis precipitated by infection has been reported in yet another known hereditary condition, Marinesco-Sjögren syndrome with demyelinating neuropathy. The biological basis of this condition remains unknown (59). Late-onset thymidine kinase 2 deficiency was also found to result in recurrent rhabdomyolysis and exercise intolerance in one patient. The authors placed importance on considering this in the differential of recurrent rhabdomyolysis due to an ongoing clinical trial (NCT03845712) (19).

Autoimmune myopathies, such as dermatomyositis and polymyositis, may present with rhabdomyolysis (63). Rhabdomyolysis may also occur in Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) immune-mediated necrotizing myopathy (IMNM) (85). However, it must be noted that baseline CK in these conditions may be more than 1000. Having symptoms of acute pain and new weakness may be clues to an episode of rhabdomyolysis (63).

Single episodes of rhabdomyolysis in individuals without hereditary predisposition occur in several clinical settings. Trauma or crush injuries occur when individuals are pinned by falling debris (10) and in comatose or anesthetized individuals when muscles are compressed for prolonged periods by the weight of the patient’s body (70). In this context, it is important to highlight a report of child abuse presenting with rhabdomyolysis (20). In these clinical settings of trauma and compression, intramuscular pressure exceeds arterial pressure and renders the muscle ischemic (67). Hypotension, respiratory depression, and metabolic inhibition (when barbiturates, carbon monoxide, or related agents are involved) may contribute to muscle injury. Acute vascular occlusion with muscle infarction also produces rhabdomyolysis (02). When circulation is restored, soluble constituents of necrotic muscle are released into the bloodstream, myoglobinuria occurs, and the cascade of medical complications of acute muscle necrosis.

Among active or well-conditioned individuals, sporadic rhabdomyolysis may also occur in setting of extreme and excessive exercise or with potentiating factors of dehydration, hyperthermia, or sickle cell trait (44; 55). Muscle glycogen depletion may play a role. Military recruits and weekend athletes engaging in unusual, intense exercise are the typical victims, and men are affected much more commonly than women. Exercise involving lengthening (eccentric) muscle contractions is often involved (08). In these circumstances (for example, running downhill), the muscle is both contracted and stretched, acting as a shock absorber. This type of muscle injury characteristically results in delayed onset muscle soreness with minimal symptoms immediately after exercise but with progressive muscle pain and restricted range of motion of affected muscle groups developing 12 to 48 hours later. The onset of rhabdomyolysis may similarly be delayed to 24 to 48 hours after exercise. Poor physical conditioning and high body mass index predisposes to exertional muscle injury. Physical conditioning is protective; however, even physically fit individuals who push beyond their normal limits may still develop catastrophic rhabdomyolysis (45; 55). Exertion-related rhabdomyolysis may also follow generalized or focal seizures as a result of muscle hyperactivity induced by drugs. Severe rapidly progressive dystonia (“dystonic storm”) has also been associated with rhabdomyolysis (37). Acquired hyperthermic syndromes such as heat stroke can lead to muscle damage and rhabdomyolysis. Prolonged hypothermia can also cause rhabdomyolysis (95).

Toxins, drugs, and substance abuse represent a major cause of acquired rhabdomyolysis. Epidemics of paralytic rhabdomyolysis in humans and animals occurred in the 1920s and 1930s near the Frishes Haff of the Baltic Sea (Haff disease) and in Sweden. The mechanism may have involved eating fish contaminated with an unknown myotoxin. Quail poisoning (coturnism) is an analogous condition in which individuals ingesting quail develop rhabdomyolysis. The biblical quail episode (Numbers 11:31-33) may represent epidemic myoglobinuria. It is unclear whether what caused this was the ingested sweet parsley seeds, henbane, or hemlock. Similar accounts have been found with other birds that have ingested hemlock. Rhabdomyolysis due to venoms of insects (hornet, tarantula) and snakes (sea snake, rattlesnake) has been documented. Mushrooms, such as Russula spp and Tricholoma spp may also induce rhabdomyolysis, especially those with genetic predispositions (04).

More recently, barbiturates, heroin, cocaine, amphetamines, phencyclidine, phenylpropanolamine, inhalants, and related agents have all been associated with rhabdomyolysis (95). Coma with crush injury (barbiturates), direct myotoxic effects (heroin, cocaine, toluene), and muscle hyperactivity (amphetamines, phencyclidine, ecstasy, and lysergic acid diethylamide) may be involved. Ethanol abuse is one of the most common causes of rhabdomyolysis. A direct toxic effect of ethanol may be the predominant mechanism of alcoholic rhabdomyolysis, but crush injury, seizures, hypokalemia, and hypophosphatemia are often present (26; 46; 63).

Several therapeutic agents can cause muscle injury and rhabdomyolysis (Table 2), including lipid-lowering agents such as clofibrate and lovastatin. The incidence of rhabdomyolysis was greatly increased when lovastatin and gemfibrozil (a fibrate related to clofibrate) were combined (73) or when cholesterol-lowering agents and cyclosporine are combined. Hypokalemia induced by K+ wasting agents (eg, amphotericin B, diuretics, laxative abuse) or pseudohyperaldosteronism (eg, glycyrrhizic acid in licorice) is an additional common mechanism of drug-related myolysis (95).

Neuroleptic malignant syndrome, a known complication of neuroleptic drugs or of abrupt discontinuation of dopaminergic agents, can cause rhabdomyolysis. In addition, neuroleptics can also be associated with rhabdomyolysis in the absence of neuroleptic malignant syndrome (58).

A serotonergic syndrome due to excess serotonin activity, resulting most commonly from the combination of a selective serotonin reuptake inhibitor with monoamine oxidase inhibitors, has also been associated with rhabdomyolysis (95). Valproic acid can cause acute metabolic decompensation in patients with underlying inborn errors of metabolism. One patient with carnitine palmitoyltransferase II deficiency had acute rhabdomyolysis triggered by valproic acid (50).

Levodopa-induced dyskinesia in advanced Parkinson disease has also been described to result in rhabdomyolysis but is very rare (74).

Metabolic derangements that may cause rhabdomyolysis include hypokalemia attributable to drugs, endocrine disorders (eg, primary aldosteronism), renal tubular acidosis, or GI disorders; hypophosphatemia (49); hyperosmolar states attributable to hyperglycemia, diabetic ketoacidosis, and hypernatremia; and heat stroke (44).

Numerous viral infections can cause rhabdomyolysis. Influenza is the most common viral etiology, followed by HIV infection and enteroviral infection. In the COVID-19 pandemic, some cases of rhabdomyolysis and concomitant rhabdomyolysis due to Sars-Cov-19 have been reported (43; 35). Some of these patients did not have any comorbidities, whereas others had diabetes mellitus, hypertension, obesity, or chronic kidney disease. There were no other new medications aside from acetaminophen. Cases presented with symptoms of fever, shortness of breath, cough, or sore throat and had accompanying myalgia or dark brown urine before or on the day of presentation to the hospital. There was no illicit drug use or prior history of rhabdomyolysis (06; 17; 27; 43; 92). The cause of muscle injury during a COVID-19 infection is still unknown. It is hypothesized that there may be direct muscle invasion of the virus or damage from the elicited immunologic response (27). It is also hypothesized that kidney injury may not only result from the effects of rhabdomyolysis but also from direct viral infiltration. Viral particles can attach to ACE2 receptors, which are present in different types of kidney cells. Inflammatory response results in additional kidney damage (66).

Lateonset -rhabdomyolysis was also reported in COVID-19-infected patients (38; 89). However, in these cases, other possible etiologies were present, and rhabdomyolysis may not entirely be due to COVID-19 infection. Medications used to treat the infection, such as meropenem, and secondary complications from the COVID-19 infection, such as hypoxia and hypercoagulability, may also lead to rhabdomyolysis (14). One case has been reported of an adolescent who developed rhabdomyolysis on presentation and died in a few days (07). However, this patient had similar symptoms a year prior; thus, it is unknown whether the patient had existing predisposing factors for developing rhabdomyolysis aside from COVID-19 infection. Rhabdomyolysis should be considered a presentation to watch out for in patients with COVID-19 infection to institute early treatment and prevent acute kidney injury.

There have been a handful of case reports of post-COVID-19 vaccination rhabdomyolysis and myositis. These patients received either mRNA COVID-19 vaccine or ChAdOx1-nCoV-19 vaccine. Few of these cases led to dialysis, multiorgan failure, or death. Four cases had an autoimmune condition that may have increased the risk of myonecrosis and rhabdomyolysis (87).

Table 1. Hereditary Causes of Rhabdomyolysis

Gene	Disease name	Baseline CK levels	Pattern of inheritance	Trigger for rhabdomyolysis
Disorders of glycogen metabolism
PYGM	Glycogen storage disease type V, McArdle disease	High	AR	Aerobic and anaerobic exercise, symptom onset within minutes
PFKM	Glycogen storage disease type VII, Tarui disease	High	AR	Aerobic and anaerobic exercise, symptom onset within minutes
ALDOA	Glycogen storage disease type XII	Normal Mild elevation, high	AR	Febrile illness, infection
ENO3	Glycogen storage disease type XIII	Normal High	AR	Aerobic and anaerobic exercise, symptom onset within minutes
PGAM2	Glycogen storage disease type X	High	AR	Aerobic and anaerobic exercise, symptom onset within minutes
PGK1	Phosphoglycerate kinase 1 deficiency	Normal High	X-linked	Aerobic and anaerobic exercise, symptom onset within minutes
PGM1	Glycogen storage disease type XIV	High	AR	Aerobic and anaerobic exercise, symptom onset within minutes, general anaesthesia
PHKA1	Glycogen storage disease type IX	?	X-linked	Aerobic and anaerobic exercise, symptom onset within minutes
PHKB			AR
Disorders of fatty acid metabolism
ACADVL	Deficiency of very-long-chain acyl-CoA dehydrogenase	Normal High	AR	Fasting, prolonged exercise, cold, infections, fever
CPT2	Carnitine palmitoyl-transferase deficiency	Normal	AR	Prolonged exercise, fasting, fever, infection, high fat intake, cold exposure, heat, emotional stress, drugs
ETFA	Glutaric aciduria type II	Normal	AR	Physical exercise, fasting, irregular diet, or infection
ETFB	Multiple acyl-coenzyme A dehydrogenase deficiency	Mildly to moderately elevated
Mitochondrial disorders
COI (MTCO1)		Normal	Maternal inheritance	Prolonged or repetitive exercise
COII (MTCO2)		Normal	Maternal inheritance	Exercise
COIII (MTCO3)		Normal	Maternal inheritance	Prolonged exercise, viral illness
DGUOK		?	AR	Viral illness
FDX1L		Normal High	AR	After exercise
HADHA	Mitochondrial trifunctional protein deficiency	Normal	AR	Strenuous activity
HADHB
ISCU	Iron-sulphur cluster deficiency myopathy	?	AR	Exercise
MTCYB		Normal	? Sporadic mutations	Exercise
POLG1	Mitochondrial recessive ataxia syndrome (MIRAS)		AD, AR	Seizures
Muscular dystrophies
ANO5	Anoctaminopathy-5	High	AR	Unprovoked
DMD	Duchenne muscular dystrophy, Becker muscular dystrophy	High	X-linked	Exercise, anesthesia
DYSF	LGMD2B, Miyoshi myopathy	High	AR	Exercise
FKTN	Fukuyama congenital muscular dystrophy	High	AR	Halothane and succinylcholine
FKRP	LGMD2I	High	AR	Exercise
Channelopathies
RYR1	Central core disease, multiminicore disease, and malignant hyperthermia	Normal or mildly to moderately elevated (usually < 1000 IU/L)	AD, AR	Exercise, heat, illness, alcohol, anesthesia
SCN4A		Normal, high	AD	Emotional stress, illness, exercise, infection
Miscellaneous
LPIN1	Phosphatidic acid phosphatase deficiency	Normal, high	AR	Febrile infection, anesthesia, and fasting
SIL1	Marinesco-Sjogren syndrome	Normal, high	AR	Febrile infection
TSEN54	Pontocerebellar hypoplasia type 2	Normal, high	AR	Hyperthermia
(63; 80; 19)

Table 2. Major Categories of Acquired (Sporadic) Rhabdomyolysis

Nontraumatic
Nonexertional causes	- Alcohol/drug abuse: ethanol, methanol, ethylene glycol, heroin, methadone, barbiturates, cocaine, caffeine, amphetamine, lysergic acid diethylamide, 3,4- methylenedioxymethamphetamine (MDMA, ecstasy), phencyclidine, benzodiazepines, toluene (from glue sniffing), gasoline/paint sniffing. - Medication: salicylates, fibric acid derivatives (bezafibrate, clofibrate, fenofibrate, gemfibrozil), neuroleptics, antipsychotics (haloperidol, fluphenazine, perphenazine, chlorpromazine), quinine, corticosteroids, statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, cerivastatin), theophylline, cyclic antidepressants, selective serotonin reuptake inhibitors, antibiotics (fluoroquinolones, pyrazinamide, trimethoprim/sulfonamide, amphotericin B, itraconazole, levofloxacin), zidovudine, benzodiazepines, antihistamines, aminocaproic acid, phenylpropanolamine, kinase inhibitors (MEK- and BRAF- inhibitors). - Toxic agents: carbon monoxide, hemlock herbs from quail (coturnism), snake bites, spider venom, massive honeybee envenomation, Tricholoma equestre (mushroom), buffalo fish, or other freshwater fish in Frishes Haff of Baltic Sea (Haff disease). - Anesthetics and neuromuscular blocking agents: barbiturates, benzodiazepines, propofol, succinylcholine in patients with Duchenne/Becker muscular dystrophy. - Infections: viral: influenza A and B, human immunodeficiency virus, enterovirus, adenovirus, coronavirus, Coxsackie virus, Epstein-Barr virus, echovirus, cytomegalovirus, herpes simplex virus, varicella-zoster virus, West Nile virus. Bacterial: Legionella species, Salmonella species, Francisella species, Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenza, Coxiella burnetii, Leptospira species, Mycoplasma species, Escherichia coli, Tetanus. Fungal and malaria infections. - Electrolyte disturbances: hyponatremia, hypernatremia, hypokalemia, hypophosphatemia (especially in conjunction with alcohol), hypocalcemia, hyperosmotic conditions. - Endocrine disorders: hypothyroidism, hyperthyroidism, diabetic ketoacidosis, nonketotic hyperosmolar diabetic coma, hyperaldosteronism. - Idiopathic inflammatory myopathies: polymyositis, dermatomyositis. - Temperature extremes: heatstroke, malignant hyperthermia, exposure to cold. - Muscle ischemia, thrombosis, embolism. - Neuroleptic malignant syndrome.
Exertional causes:	- Extreme physical exertion, physical overexertion in Sickle cell disease. - Status epilepticus.
Traumatic: multiple injury, crush injury, bombings, earthquakes, building collapse, mine accidents, train or motor vehicle accidents, high-voltage electrical injury, extensive third-degree burns.
	- Vascular/orthopedic surgery: intraoperative use of tourniquets, tight dressings or casts, prolonged application of air splints or pneumatic antishock garments and clamping of vessels during surgery. - Prolonged immobility: immobilization after trauma, anesthesia, coma, drug or alcohol-induced unconsciousness.
(101; 63; 25; 84; 04).

Mechanism of injury. Myoglobin is an approximately 17,500 molecular weight heme protein found in the cytoplasm of skeletal muscle in concentrations of 1 to 4 mg/g wet weight: lower in low-oxidative fibers or deconditioned muscle, higher in conditioned, highly oxidative muscle. Myoglobin has a greater affinity for oxygen than hemoglobin at low partial oxygen pressures and plays a critical role in mediating oxygen transport from red cells to muscle mitochondria (97). The exterior of the myoglobin molecule is composed mainly of hydrophilic residues, thus facilitating molecular movement and oxygen transfer in concentrated solutions. These same properties account for the rapid diffusion of myoglobin from lysed muscle cells into the blood.

The mechanisms of muscle injury in rhabdomyolysis are likely diverse, but two general themes are common. Sudden, widespread muscle injury due to trauma, toxins, venoms, or drugs (especially intravenous drugs) suggests that these agents cause direct muscle membrane injury. Muscle necrosis may follow due to increased cellular levels of sodium and calcium.

Another common theme is a low level of cellular energy availability relative to demand, as in muscle ischemia, carbon monoxide poisoning, exhaustive exercise, or muscle energy defects. Illustrative are metabolic myopathies in which a superimposed stress (usually exercise) exposes a weak link in energy production and results in an acute energy crisis. However, the precise mechanism by which impaired muscle energy availability produces muscle cellular injury is unknown. One hypothesis is that ATP is depleted to critical levels. Some data suggest that ATP produced via substrate-level phosphorylation in glycolysis preferentially supports or regulates sarcolemmal function (36; 72). This could account for the propensity of muscle glycolytic defects to produce recurrent exertional rhabdomyolysis. Alternatively, muscle injury could be mediated by hydrolysis products of ATP. A small decline in ATP is associated with a much greater relative increase in the concentration of ADP, inorganic phosphate (Pi), and related metabolites (eg, [H+]). Physiologic studies suggest that high levels of these metabolites may impair muscle function by inhibiting enzymes (ATPases) that couple ion transport to ATP hydrolysis, leading to premature muscle fatigue and cramping.

A decrease of Na+, K+ - ATPase activity reduces the transmembrane electric voltage and promotes cellular accumulation of sodium ions. The resulting diminution of the sodium gradient reduces 2Na+: Ca++ exchange, promoting accumulation of Ca++ in the cytosol that, in turn, can activate hydroxylases, nucleases, phospholipases, and neutral proteases. Activation of these enzymes has been related to sarcolemmal injury and other organelle damage, including the mitochondria, leading to further ATP depletion and production of free radicals (47; 72).

Renal failure is more likely to occur in the presence of volume depletion, fever, metabolic acidosis, and the excretion of concentrated, acid urine (12). There appears to be a direct relationship between myoglobin concentration in the urine and the propensity to develop acute renal failure (24).

There are three mechanisms believed to cause renal failure:

(1) Renal vasoconstriction that results from reduced renal blood flow due to decreased extracellular fluid causing activation of the renin angiotensin aldosterone system. In addition, myoglobin appears to form complexes with nitric oxide, which exaggerates vasoconstriction of renal vasculature.

(2) Formation of intratubular casts as myoglobin interacts with Tamm-Horsfall protein, which can be potentiated further by decreased renal blood flow and acidic environment.

(3) Direct toxicity of myoglobin to kidney tubular cells as heme oxygenase-1 in proximal tubular cells degrades myoglobin and releases free iron. Reactive oxygen species are then made from redox cycling between ferric (Fe 3+) and ferryl (Fe4) myoglobin, which has negative effects on the tubular cells and surrounding organelles. This myoglobin-induced lipid peroxidation is prevented in alkaline conditions because Fe4 is stabilized in this pH, decreasing the reactivity of myoglobin to lipids and lipid hydroperoxides.

Epidemiology

Sporadic rhabdomyolysis can occur in normal individuals. The global incidence is still unknown, but certain populations may have increased risk, such as morbidly obese patients, chronic lipid-lowering drug users, and postoperative patients (15). The fact that only a few subjects exposed to exhaustive exercise, drugs, or toxins develop this complication is consistent with the possibility that unrecognized genetic factors may influence individual susceptibility. For example, the sickle cell trait apparently increases the risk of exertional rhabdomyolysis, particularly at high altitudes, possibly by impairing blood flow to working muscle. Additionally, a study assessing the genetic risk factors associated with lipid-lowering drug-induced myopathies reported a higher prevalence of underlying muscle disease than expected in the general population. In this study, among the patients who developed statin-induced myopathy, 10% were heterozygous or homozygous for mutations causing common hereditary metabolic myopathies: 6.5% had myoadenylate deaminase deficiency, 0.9% had carnitine palmitoyl transferase II deficiency, and 0.9% had McArdle disease. The authors concluded that the effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms might account for myopathic outcomes in certain high-risk groups (93).

Other epidemiological studies assessing the etiology of sporadic rhabdomyolysis disclose variable results. In a cohort of 177 cases of rhabdomyolysis, Alpers and Jones showed that exertion-induced rhabdomyolysis occurred in 35%, trauma in 20%, toxins in 13%, infections in 7%, heat illness in 7%, seizures in 4%, metabolic myopathy in 3%, and endocrine disturbances in 2% (05). In a study by Melli and colleagues, illicit drugs, alcohol, and prescribed drugs were responsible for 46% of the cases of rhabdomyolysis in a cohort of 475 hospitalized patients (57). Among the prescription drugs, antipsychotics, statins, zidovudine, colchicine, selective serotonin reuptake inhibitors, and lithium were the most frequently involved. Multiple factors may be detected in 9% to 60% of cases (26; 57; 05; 01).

A study by Paternostro and colleagues examined the incidence and clinical spectrum of rhabdomyolysis in general neurology (68). Of 248 patients diagnosed with rhabdomyolysis, seizures (31.9%), illicit drug use or alcohol (9.7%), and exercise (8.5%) were the most common triggers. Common diagnoses associated with high cases of rhabdomyolysis were myopathies (49.8/1,000 person-years, 95% CI 32.3–67.4), followed by epilepsy (16.4/1,000 person-years, 95% CI 12.8–20.0) and stroke (11.9/1,000 person-years, 95% CI 8.4–15.4). In this cohort, 60.5% were males and had a median age of 49.6 (30.5-66.8) and a BMI of 25.4 (22.8-29.0).

An underlying muscle metabolic error is likely in patients with recurrent rhabdomyolysis and a positive family history, or in whom common acquired causes of rhabdomyolysis can be excluded. Analysis of 77 patients with adult-onset rhabdomyolysis, where alcohol and drug abuse had been excluded, showed that 46% of the patients had an underlying enzyme deficiency. The most frequent enzyme defect was carnitine palmitoyltransferase II deficiency (22%), followed by phosphorylase deficiency (13%) and phosphorylase kinase deficiency (5%) (91). Analysis of 22 adult patients from Finland with recurrent rhabdomyolysis showed that 23% had an identifiable enzyme deficiency, and 18% had muscle dystrophy or myopathy. The most frequent enzyme deficiency among this population was phosphorylase deficiency (18%), followed by phosphofructokinase deficiency (5%) and phosphorylase kinase deficiency (5%). The authors concluded that the prevalence of enzyme defects causing rhabdomyolysis might vary in different populations (53).

The exact incidence of rhabdomyolysis in the pediatric population is unclear. In a retrospective review of 19 children with acute rhabdomyolysis, where cases with recurrent rhabdomyolysis had been excluded, the most frequent etiology was trauma (26%), followed by nonketotic hyperosmolar coma (11%), viral myositis (11%), dystonia (11%), and malignant hyperthermia (11%) (96). In a cohort of 210 children with acute rhabdomyolysis, Mannix and colleagues found that 38% had viral myositis, 26% had trauma, and 5% had connective tissue disease (54). A third cohort of 130 pediatric cases of rhabdomyolysis, 22% had viral myositis, 18% had trauma, 18% had surgery, 9% had hypoxia, 6% had drug reaction, and 1% had metabolic myopathy (71). In 13% of cases, no definite diagnosis could be made. Among 52 pediatric patients with nontraumatic rhabdomyolysis, 72% of cases were due to viral infection, with influenza A and B being the most common etiologies, 9.3% due to physical exertion, and 1.9% were unidentified (51). Other causes were convulsion and dystonia.

Diagnostic workup

Diagnosis involves excluding other causes of pigmenturia, such as hematuria, hemoglobinuria, or porphyria. Next, the cause of myoglobinuria should be established. The workup should include a careful history and a toxicology screen to identify drugs or toxins known to produce rhabdomyolysis and screening for metabolic derangements known to cause rhabdomyolysis (Table 2). Extensive work-up for rhabdomyolysis is indicated for recurrent or family history of rhabdomyolysis and myalgia or muscle cramps, especially at rest. Glycogen metabolism disorders should be suspected in early rhabdomyolysis from activity, with elevated baseline CK. In muscle phosphorylase deficiency, second wind phenomenon during exercise occurs wherein fatigue and pain abate after resting and activity can then be resumed. Phosphofructokinase deficiency may have the same symptoms as McArdle disease but without the second wind phenomenon and with an additional finding of compensated hemolysis, evidenced by hyperuricemia and reticulocytosis. Lactate dehydrogenase deficiency can be considered in those with reduced LDH levels, erythematous rash on extensor surfaces, or uterine stiffness in pregnancy. In contrast, fatty acid oxidation disorders are suspected with rhabdomyolysis triggered by prolonged submaximal exertion, fasting, stress or illness. These symptoms are suggestive of an inborn error of muscle metabolism and if suspected, appropriate diagnostic testing should be undertaken with an ischemic forearm exercise test, muscle biopsy, biochemical testing for known metabolic errors, or a genetic test. If muscle biopsy is indicated, obtaining the muscle sample at least 4 to 6 weeks after the patient has recovered from rhabdomyolysis is recommended. Better diagnostic outcomes with biopsies are observed in patients with myopathic electromyography, second wind phenomenon, or muscle hypertrophy/atrophy (63). Zutt and colleagues suggested the illustrated scheme in working up cases with rhabdomyolysis (101).

Antibody tests may also be warranted, especially in those with autoimmune myopathies (63).

Rhabdomyolysis diagnostic workup

Suggested workup scheme for cases of rhabdomyolysis. (Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24(8):651-9.)

A study by Xu and colleagues retrospectively looked at 50 patients diagnosed with rhabdomyolysis after having an ultrasound (98). Among these, 26 were diagnosed with exertional rhabdomyolysis, and 12 underwent serology tests only after changes suspicious for rhabdomyolysis were detected by ultrasound. Imaging found blurred muscle fiber structure, ground glass changes, or muscle thickening. Patients diagnosed earlier were found to have shorter hospital stays. The authors then included ultrasound as a possible tool in early diagnosis of exertional rhabdomyolysis.

Management

The major complications of rhabdomyolysis are outlined in Table 3. Because volume depletion greatly increases the risk of acute renal failure, early and adequate fluid replacement (normal saline or one-half normal saline in dextrose) is essential to maintain renal perfusion. Ideally, this should be started within 6 hours of symptoms onset (16; 28). Most studies recommend maintaining urine output of 200 to 300 ml/hour until rhabdomyolysis resolves. In a systematic review of the treatment of exertional rhabdomyolysis, the range of intravenous fluid resuscitation rate ranged from 120 to 300 ml/hour. The average hospital stay length was 4.5 days (55).

Alkalization of the urine with intravenous sodium bicarbonate reduces cast formation and, thereby, promotes excretion of myoglobin. Increasing urine pH to around 6.5 may help reduce heme toxicity to the tubules (03). A systematic review and meta-analysis on rhabdomyolysis treatment looked at 12 studies, the majority of them retrospective, to aid in creating management guidelines. Consequently, the practice management guidelines from the Eastern Association for the Surgery of Trauma recommended against treatment with bicarbonate or mannitol in patients with rhabdomyolysis due to conflicting and low-quality evidence and failure to show improvement in the incidence of acute renal failure. However, they did recommend aggressive intravenous fluid resuscitation to improve outcomes of ARF and lessen the need for dialysis (79).

Oliguria is an independent risk factor for compartment syndrome or acute respiratory distress syndrome. Persistent oliguria (urine flow less than 20 cc/hour) despite correction of hypotension and using mannitol, furosemide, and sodium bicarbonate suggests acute tubular necrosis. Further volume replacement in this setting risks interstitial and pulmonary edema. Such patients often require early and aggressive hemodialysis or high-flux dialysis to reduce myoglobin (72; 81).

Hyperkalemia due to intracellular potassium release from necrotic muscle may cause life-threatening cardiac arrhythmias or even cardiac arrest, particularly in the setting of renal failure and, thus, should be rapidly corrected (16). The effect of hyperkalemia is potentiated by hypocalcemia, attributable to hyperphosphatemia and deposition of calcium salts in injured muscle. The electrocardiogram assesses hyperkalemic cardiotoxicity more sensitively than serum [K+] levels per se. Emergent treatment of hyperkalemia includes intravenous glucose and insulin, calcium salts, and hyperventilation to promote cellular uptake of potassium. Oral disodium polystyrene sulfonate is useful but acts slowly. Hemodialysis may be required. Repeating blood tests 24 to 72 hours from initial draws is warranted to monitor the trend of CK and electrolytes (51).

There has been anecdotal evidence of dexamethasone use in rhabdomyolysis. Dexamethasone was effective in alleviating symptoms and decreasing CK levels in two pediatric cases, one with an LPIN1 gene mutation of unknown significance and the other with exertion and respiratory tract infection as potential triggers for rhabdomyolyses (86).

Muscle compartment syndrome may require fasciotomy to avert limb-threatening ischemia and peripheral nerve injury.

Table 3. Mechanisms and Management of Complications of Rhabdomyolysis and Myoglobinuria

Complication (mechanism)	Management
Acute renal failure (toxic effect of myoglobin, potentiated by hypovolemia, acidosis)	• Maintain urine output with aggressive intravenous fluid resuscitation • Hemodialysis
Hyperkalemia (release of intracellular K+, impaired K+ clearance by kidney due to renal insufficiency)	• Glucose + insulin • Calcium administration • K+ binding resins • Hemodialysis
Hypocalcemia (deposition of calcium salts in injured muscle)—potentiates cellular effects of hyperkalemia	• No specific treatment • Monitor ECG for effects of hyperkalemia; treat hyperkalemia as above
Hyperphosphatemia (release of phosphate from injured muscle)	• No specific treatment
Hemorrhage (related to disseminated intravascular coagulation thrombocytopenia, fibrinolysis, capillary injury)	• Fresh frozen plasma
Adult respiratory distress syndrome	• Artificial ventilation
Ischemic bowel syndrome	• Correct hypovolemia
Compartment syndrome (ischemia due to muscle injury and swelling)	• Fasciotomy may be required

Outcomes

Among the exertional rhabdomyolysis cohort, after the resolution of kidney injury and return of CK to baseline, slow progression or graded return to activity was done.

References

01: Abudalou M, Mohamed AS, Vega EA, Al Sbihi A. Colchicine-induced rhabdomyolysis: a review of 83 cases. BMJ Case Rep 2021;14(7):e241977. PMID 34290008
02: Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischaemia and claudicants treated by revascularization. Br J Surg 1992;79:1026-9. PMID 1422711
03: Ahmad S, Anees M, Elahi I, Mateen FE. Rhabdomyolysis leading to acute kidney injury. J Coll Physicians Surg Pak 2021;31(2):235–37. PMID 33645199
04: Aleckovic-Halilovic M, Pjanic M, Mesic E, Storrar J, Woywodt A. From quail to earthquakes and human conflict: a historical perspective of rhabdomyolysis. Clin Kidney J 2020;14(4):1088-96. PMID 33841854
05: Alpers JP, Jones LK Jr. Natural history of exertional rhabdomyolysis: a population-based analysis. Muscle Nerve 2010;42(4):487-91. PMID 20730874
06: Alrubaye R, Choudhary H. Severe rhabdomyolysis in a 35-year-old woman with COVID-19 due to SARS-CoV-2 infection: a case report. Am J Case Rep 2020;21:e926733. PMID 32801291
07: Anwar H, Al Lawati A. Adolescent COVID-19-associated fatal rhabdomyolysis. J Prim Care Community Health 2020;11:2150132720985641. PMID 33357150
08: Armstrong RG, Warren GL, Warren JA. Mechanisms of exercise-induced muscle fibre injury. Sports Med 1991;12:184-207.
09: Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med 2007;2(3):210-8. PMID 17909702
10: Better OS. The crush syndrome revisited (1940-1990). Nephron 1990;55:97-103. PMID 2194135
11: Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361(1):62-72. PMID 19571284
12: Bywaters EG. Ischemic muscle necrosis. JAMA 1944;124:1103-9.
13: Cagliani R, Comi GP, Tancredi L, et al. Primary beta-sarcoglycanopathy manifesting as recurrent exercise-induced myoglobinuria. Neuromusc Dis 2000;11:389-94.
14: Chan KH, Farouji I, Hanoud AA, Slim J. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med 2020;38(7):1548.e1-3. PMID 32414522
15: Chakravartty, S, Sarma DR, Patel AG. Rhabdomyolysis in bariatric surgery: a systematic review. Obes Surg 2013;23(8):1333-40. PMID 23564464
16: Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care 2016;20(1):135. PMID 27301374
17: Chedid NR, Udit S, Solhjou Z, Patanwala MY, Sheridan AM, Barkoudah E. COVID-19 and rhabdomyolysis. J Gen Intern Med 2020;35(10):3087-90. PMID 32671722
18: David WS. Myoglobinuria. Neurol Clin 2000;18(1):215-43. PMID 10658177
19: de Fuenmayor-Fernández de la Hoz CP, Morís G, Jiménez-Mallebrera C, et al. Recurrent rhabdomyolysis and exercise intolerance: a new phenotype of late-onset thymidine kinase 2 deficiency. Mol Genet Metab Rep 2021;26:100701.** PMID 33457207
20: DiGiacomo JC, Frankel H, Haskell RM, Rotondo MF, Schwab CW. Unsuspected child abuse revealed by delayed presentation of periportal tracking and myoglobinuria. J Trauma 2000;49:348-50. PMID 10963553
21: DiMauro S. Exercise intolerance and the mitochondrial respiratory chain. Ital J Neurol Sci 1999;20:387-93. PMID 10937858
22: DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984-99. PMID 11439374
23: Emmanuele V, Sotiriou E, Shirazi M, et al. Recurrent myoglobinuria in a sporadic patient with a novel mitochondrial DNA tRNA(Ile) mutation. J Neurol Sci 2011;303(1-2):39-42. PMID 21324494
24: Feinfeld DA, Cheng JT, Beysolow TD, Briscoe AM. A prospective study of urine and serum myoglobin levels in patients with acute rhabdomyolysis. Clin Nephrol 1992;38:193-5. PMID 1424305
25: Finsterer J. Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case. Rev Med Chile 2020;148 (11):1684-9. PMID 33844777
26: Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine 1982;61:141-52. PMID 7078398
27: Gefen AM, Palumbo N, Nathan SN, Singer PS, Castellanos-Reyes LJ, Sethna CB. Pediatric COVID-19-associated rhabdomyolysis: a case report. Pediatr Nephrol 2020;35(8):1517-20. PMID 32447505
28: Gupta A, Thorson P, Penmatsa KR, Gupta P. Rhabdomyolysis: revisited. Ulster Med J 2021;90(2):61-9. PMID 34276082
29: Hall RE, Henriksson KG, Lewis SF, Haller RG, Kennaway NG. Mitochondrial myopathy with succinate dehydrogenase and aconitase deficiency: abnormalities of several iron-sulfur proteins. J Clin Invest 1993;92:2660-6. PMID 8254022
30: Haller RG, Knochel JP. Metabolic myopathies. In: Johnson RT, Griffin JW, editors. Current therapy in neurologic disease. St. Louis: Mosby-Year Book, 1993:397-402.
31: Haviv R, Zeharia A, Belaiche C, Haimi Cohen Y, Saada A. Elevated plasma citrulline: look for dihydrolipoamide dehydrogenase deficiency. Eur J Pediatr 2014;173(2):243-5. PMID 23995961
32: Hed R. Myoglobinuria in man. With special reference to a familial form. Acta Med Scand Suppl 1955;303:1-107. PMID 14387578
33: Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis -- an overview for clinicians. Crit Care 2005;9(2):158-69. PMID 15774072
34: Ivanyuk A, Segarra NG, Buclin T, et al. Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution. Neuromuscular Disorders 2018;28(10):865-67. PMID 30217487
35: Jahnke VS, Poloni JAT, Moreira Neves CA, Peter C, Thompson CE, Rotta LN. Acute kidney injury associated with rhabdomyolysis in a patient with COVID-19. J Bras Nefrol 2021;S0101-28002021005025301. PMID 33704346
36: James JH, Fang CH, Schrantz SJ, Hasselgren PO, Paul RJ, Fischer JE. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. J Clin Invest 1996;98:2388-97. PMID 8941658
37: Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology 1982;32:1195-7. PMID 6889706
38: Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis 2020;26(7):1618-20.** PMID 32197060
39: Jurkat-Rott K, Lerche H, Lehmann-Horn F. Skeletal muscle channelopathies. J Neurol 2002;249:1493-502. PMID 12420087
40: Kagen LJ. Myoglobin: biochemical, physiological, and clinical aspects. New York: Columbia Univ Pr, 1973.
41: Kahraman AB, Yildiz Y, Gokmen-Ozel H, Kadayifcilar S, Sivri S. Successful management of rhabdomyolysis with triheptanoin in a child with severe long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency. Neuromuscul Disord 2023;33(4):315-8. PMID 36893607
42: Kamijo K, Indo Y, Souri M, et al. Medium chain 3-ketoacyl-coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid beta-oxidation. Pediatr Res 1997;42:569-76.
43: Khosla SG, Nylen ES, Khosla R. Rhabdomyolysis in patients hospitalized with COVID-19 infection: five case series. J Investig Med High Impact Case Rep 2020;8:2324709620984603.** PMID 33371733
44: Knochel JP. Heat stroke and related heat stress disorders. Dis Mon 1989;35:301-77. PMID 2653754
45: Knochel JP. Catastrophic medical event with exhaustive exercise: "white collar rhabdomyolysis." Kidney Int 1990;38:709-19. PMID 2232508
46: Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med 1992;92:455-7. PMID 1580291
47: Knochel JP. Mechanisms of rhabdomyolysis. Curr Opin Rheumatol 1993;5:725-31. PMID 8117534
48: Knochel JP. Pigment nephropathy. In: Greenberg A, editor. Primer on kidney diseases. The National Kidney Foundation, 1994:149-52.
49: Knochel JP. Potassium deficiency and rhabdomyholysis. J Mol Cell Cardiol 1995;27:1-9.
50: Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromusc Dis 2001;11:757-9. PMID 11595519
51: Kuok CI, Chan WK. Acute kidney injury in pediatric non-traumatic rhabdomyolysis. Pediatr Nephrol 2021;36(10):3251-7. PMID 33851263
52: Larsson LE, Linderholm H, Muller R, Ringqvist T, Sornas R. Hereditary metabolic myopathy with paroxysmal myoglobinuria due to abnormal glycolysis. J. Neurol Neurosurg Psychiatry 1964;27:361-80.
53: Lofberg M, Jankala H, Paetau A, Harkonen M, Sormer H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 1998;98:268-75. PMID 9808277
54: Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 2006;118(5):2119-25. PMID 17079586
55: Manspeaker S, Henderson K, Riddle D. Treatment of exertional rhabdomyolysis in athletes: a systematic review. JBI Database of Systematic Rev Implement Rep 2016;14(6):117-47. PMID 27532656
56: Mathews KD, Stephan CM, Laudbenthal K, et al. Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I. Neurology 2011;76(2):194-5. PMID 21220724
57: Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005;84:377-85. PMID 16267412
58: Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395-405. PMID 8887994
59: Merlini L, Gooding R, Lochmuller H, et al. Genetic identity of Marinesco-Sjogren/myoglobinuria and CCFDN syndromes. Neurology 2002;58:231-6. PMID 11805249
60: Mochel F, Knight MA, Tong WH, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 2008;82:652-60. PMID 18304497
61: Mori K, Mizuno J, Nagaoka T, Harashima T, Morita S. Combined spinal-epidural anesthesia for cesarean section in a parturient with myotonic dystrophy [Article in Japanese]. Masui 2010;59(8):1000-3. PMID 20715526
62: Moslehi R, Langlois S, Yam I, Friedman JM. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Hum Genet 1998;76:21-7. PMID 9508059
63: Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve 2015;51(6):793-810. PMID 25678154
64: Nasu K, Sugano T, Yoshimatsu J, Narahara H. Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy. Gynecol Obstet Invest 2006;6:53-5. PMID 16192734
65: Ogoyama M, Takahashi H, Kobayashi Y, Usui R, Matsubara S. Ritodrine-induced rhabdomyolysis, infantile myotonic dystrophy, and maternal myotonic dystrophy unveiled. J Obstet Gynaecol Res 2017;43(2):403-7. PMID 27987333
66: Ostermann M, Lumlertgul N, Forni LG, Hoste E. What every intensivist should know about COVID-19 associated acute kidney injury. J Crit Care 2020;60:91-5. PMID 32777758
67: Owen CA, Mubarak SJ, Hargrens AR, Rutherford L, Garetto LP, Akeson WH. Intramuscular pressures with limb compression. Clarification of the pathogenesis of drug-induced muscle compartment syndrome. N Engl J Med 1979;300:1169-72. PMID 431646
68: Paternostro C, Gopp L, Tomschik M, et al. Incidence and clinical spectrum of rhabdomyolysis in general neurology: a retrospective cohort study. Neuromuscul Disord 2021;31(12):1227-34. PMID 34711480
69: Paulsen G, Benestad HB. Muscle soreness and rhabdomyolysis. Tidsskrift for Den Norske Legeforening 2019;139(10). PMID 31238673
70: Penn. Myoglobinuria. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: McGraw Hill, 1994:1679-96.
71: Perreault S, Birca A, Piper D, Nadeau A, Gauvin F, Vanasse M. Transient creatine phosphokinase elevations in children: a single-center experience. J Pediatr 2011;159(4):682-5. PMID 21592501
72: Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 2014;18(3):1-8. PMID 25043142
73: Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5. PMID 2355431
74: Pitakpatapee Y, Srikajon J, Sangpeamsook T, Srivanitchapoom P. Rhabdomyolysis associated with severe levodopa-induced dyskinesia in Parkinson's disease: a report of two cases and literature review. Tremor Other Hyperkinet Mov (N Y) 2021;11:39. PMID 34692231
75: Premru V, Kovač J, Ponikvar R. Use of myoglobin as a marker and predictor in myoglobinuric acute kidney injury. Ther Apher Dial 2013;17(4):391-5. PMID 23931877
76: Ruitenbeek W, Poels PJ, Turnbull DM, et al. Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 1995;58:209-14. PMID 7876853
77: Sasuga M, Matsukawa T, Ookawa I, Tamaki F, Masamune T, Kumazawa T. Anesthetic management of three patients with myotonic dystrophy in a family [Article in Japanese]. Masui 2004;53(3):269-72. PMID 15071876
78: Saudubray JM, Martin D, De Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inher Metab Dis 1999;22:488-502. PMID 10407781
79: Sawhney JS, Kasotakis G, Goldenberg A, et al. Management of rhabdomyolysis: a practice management guideline from the Eastern Association for the Surgery of Trauma. Am J Surg 2022;224(1 Pt A):196-204. PMID 34836603
80: Scalco RS, Gardiner AR, Pitceathly RD, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis 2015;10:51. PMID 25929793
81: Scharf C, Liebchen U, Paal M, Irlbeck M, Zoller M, Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care 2021;25(1):41. PMID 33509234
82: Schifman RB, Luevano DR. Value and use of urinalysis for myoglobinuria. Arch Pathol Lab Med 2019;143(11):1378-81. PMID 31116043
83: Shaag A, Saada A, Berger I, et al. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet 1999;82(2):177-82. PMID 9934985
84: Stahl K, Rastelli E, Schoser B. A systematic review on the definition of rhabdomyolysis. J Neurol 2020;267(4) 877-82. PMID 30617905
85: Stroie OP, Boster J, Surry L. Statin-induced immune-mediated necrotizing myopathy: an increasingly recognized inflammatory myopathy. Cureus 2020;12(5):e7963. PMID 32523820
86: Summerlin ML, Regier DS, Fraser JL, et al. Use of dexamethasone in idiopathic, acute pediatric rhabdomyolysis. Am J Med Genet A 2021;185(2):500-7. PMID 33300687
87: Sutcu M, Gul D, Atik F, Kara M. Rhabdomyolysis after BNT162b2 mRNA COVID-19 vaccine in an adolescent male. Malawi Med J 2022;34(2):154-6. PMID 35991822
88: Tanaka M, Ino H, Ohno K, et al. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 1990;336(8728):1452. PMID 1978914
89: Taxbro K, Kahlow H, Wulcan H, Fornarve A. Rhabdomyolysis and acute kidney injury in severe COVID-19 infection. BMJ Case Rep 2020;13(9):237616.** PMID 32878841
90: Tein I, De Vivo DC, Hale DE, et al. Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol 1991;30:415-9. PMID 1835339
91: Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990;27:181-5. PMID 2156480
92: Valente-Acosta B, Moreno-Sanchez F, Fueyo-Rodriguez O, Palomar-Lever A. Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19 unusual association of diseases/symptoms. BMJ Case Rep 2020;13(6):e236719. PMID 32587121
93: Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34(2):153-62. PMID 16671104
94: Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988;148(7):1553-7. PMID 3382301
95: Warren JD, Blumberg PC, Thompson PD. Rhabdomyolysis. Muscle Nerve 2002;25:332-47. PMID 11870710
96: Watemberg N, Leshner RL, Armstrong BA, Lerman-Sagie T. Acute pediatric rhabdomyolysis. J Child Neurol 2000;15:222-7. PMID 10805187
97: Wittenberg BA, Wittenberg JB. Transport of oxygen in muscle. Annu Rev Physiol 1989;51:857-78. PMID 2653210
98: Xu Q, Tian M, Xia J, Zhu W, Yang L. Application of ultrasonography in the diagnosis of rhabdomyolysis. Ultrasound Med Biol 2021;47(12):3349-55. PMID 34535325
99: Yuasa H, Onoda Y, Kitaura A, Mino T, Tsukimoto S, Nakao S. Anesthesia management in a patient with very long-chain acyl-coenzyme A dehydrogenase deficiency. JA Clin Rep 2020;6(1):72. PMID 32939699
100: Zeharia A, Shaag A, Houtkooper RH, et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008;83:489-94. PMID 18817903
101: Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24(8):651-9. PMID 24946698

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Mohamed Kazamel MD

Dr. Kazamel of the University of Alabama at Birmingham has no relevant financial relationships to disclose.
See Profile
Carmela San Luis MD

Dr. San Luis of Guthrie Clinic in Corning, New York has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Jun Ho Kim MD
Emma Ciafaloni MD FAAN
Ronald G Haller MD, James P Knochel MD (original authors), and Roser Pons MD

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: male>female, >1:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Myoglobinuria: 791.3
ICD-10: Myoglobinuria: R82.1
OMIM: Myoglobinuria, familial paroxysmal paralytic: #268200

Ryanodine receptor 1; RYR1: *180901

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Rhabdomyolysis (myoglobinuria)

Associated Disorders

Aconitase deficiency
Acute renal failure
Acute respiratory distress syndrome
Carnitine palmityl transferase deficiency
Disseminated intravascular coagulation
- Dystrophin deficiency
- Endocrine disorders
- Gastrointestinal disorders
- Glycogen storage diseases
- Influenza
- Lactate dehydrogenase deficiency
- Legionnaire disease
- Lipid myopathies
- Long-chain acyl CoA dehydrogenase deficiency
- Muscle glycolytic defect
- Phosphofructokinase deficiency
- Phosphoglycerate kinase deficiency
- Phosphoglycerate mutase deficiency
- Phosphorylase deficiency
- Renal tubular acidosis
- Short-chain L-3 hydroxyacyl CoA dehydrogenase deficiency
- Succinate dehydrogenase deficiency
- Toxic shock syndrome
- Trifunctional protein deficiency
- Very long-chain acyl-CoA dehydrogenase deficiency

Differential Diagnosis

other causes of pigmenturia
inborn error of metabolism

Also Relevant

Alcoholic myopathy
Becker muscular dystrophy
Carnitine palmitoyltransferase II deficiency
Drug-induced myopathies
Long-chain fatty acid oxidation defects
- Malignant hyperthermia
- Nonlysosomal muscle glycogenoses

Clinical Categories

Neuromuscular Disorders

Web References

Testing

Mitochondrial DNA Deletion Syndromes

Rhabdomyolysis (myoglobinuria)

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Hereditary Causes of Rhabdomyolysis

Table 2. Major Categories of Acquired (Sporadic) Rhabdomyolysis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Table 3. Mechanisms and Management of Complications of Rhabdomyolysis and Myoglobinuria

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Drug-induced myasthenic syndromes

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

This is an article preview.
Start a Free Account
to access the full version.